Under construction – not a live service
Sign in

Information, not a decision

Head and neck cancer: tumour board sheet

Dated public registry data. It contains no treatment recommendation. 14 Nov 2026

Open trials (1027)

NCT07279116Phase 1ABY-029 Head & Neck Phase 1 TrialRecruiting
NCT07667400Phase 1/2Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate CancerRecruiting
NCT07360314Phase 1Anti-Ly6E Exatecan ADC M7437 in Advanced Solid TumorsRecruiting
NCT07741643Phase 1Study Evaluating the Safety and Feasibility of Panitumumab-IRDye800 and [18F]NOTA-ABY-030 for Targeted Dual-Modality Imaging (TDMI) in Head and Neck Squamous Cell CarcinomaRecruiting
NCT04671667Phase 2Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell CarcinomaRecruiting
NCT05172245Phase 1Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck CancerRecruiting
NCT06589804Phase 3Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous TreatmentRecruiting
NCT05136196Phase 2BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot StudyRecruiting
NCT07932067Phase 2Circulating Tumor DNA-Informed Adjuvant Therapy for Intermediate-Risk Head and Neck CancerNot yet recruiting
NCT04966481Phase 3Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 InhibitorRecruiting
NCT06627270Phase 2Antibiotic Treatment Effects on Intratumoral Bacteria Modulation in Surgical Patients With Oral CancerRecruiting
NCT07741565Early Phase 1Window Trial of Intratumoral (IT) Neoadjuvant Fluorescently Labelled Nivolumab (nivo800) in Head and Neck Squamous Cell Carcinoma (HNSCC)Recruiting

1015 more in the doctor's list on the site.

Phase 3 trials that ended in the last 90 days

NCT0679096625 Aug 2026Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaStopped early

Guidelines

Links only: read the guideline itself.

Made from the public data of Frontlight Research. Source: ClinicalTrials.gov. 14 Nov 2026

https://frontlightresearch.com/en/doctor/head-and-neck-cancer/tumor-board